Takeda Pharmaceutical Company
武田制药
elsewhere's corpus does not cover Takeda Pharmaceutical Company as a subject in its own right. The only mentions are incidental: a 2025 pipeline licensing deal with Innovent Biologics noted by FreeS Fund, and a 2024 acquisition of five cardiovascular and metabolic drugs by CBC Group reported by 暗涌Waves . No entity card or dedicated profile material is present in the bundle.
AI-generated — may contain errors, please verify.
Takeda Pharmaceutical CompanyCompany
武田制药
渲染中…
Mentioned in 4 articles
Coverage
FreeS Fund's Li Feng 2025 Year-End Share: The Logic and Outlook of AI Investment
Why Is This AI Boom Unprecedented? What Happens Next for AI Investment?
Fu Wei, who spent ten years doing control buyouts, said they are the blue-collar workers of the investment industry.
Go with the flow.
A Clever Exit Move: Turning 180 Million in Three Years
What "divine" new money-making method?
Akasuo Biotech Raises RMB 20 Million in Angel Round | Led by Oasis Capital
Building Next-Generation General-Purpose High-Throughput Microsphere Production Infrastructure
